The phosphodiesterase type 5 (PDE5) inhibitor udenafil could improve cognition, depression, and somatization in men with erectile dysfunction (ED), Korean researchers say. 

Their study, published last spring in the International Journal of Impotence Research, built on previous work.

This study involved 60 men with a mean age of 60 years. The participants had had ED for an average of 16 to 18 months.

Half of the men took 50 mg of udenafil daily for eight weeks.  The other half took a placebo for the same duration.

Using a variety of assessment tools, including the International Index of Erectile Function (IIEF), the researchers evaluated the men at baseline and again at the eight-week point.

They found that the men taking udenafil had greater improvements in ED, depression, general cognition, depression, and somatization when compared to the placebo group.

Please click here for more information on this study.

For a limited time, ISSM members may publish in Sexual Medicine, the ISSM's open access journal, for $100.

This subsidy applies to 20 papers authored by ISSM members that are accepted for publication in Sexual Medicine. For eligible papers, ISSM members pay a special discounted rate of $100 (regularly $500).

This offer is available to ISSM members only. Please click here to submit your manuscript. More information about publishing in Sexual Medicine may be found here.

Further details about this program are available here.